Gantenerumab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Alzheimer DiseaseDementia

171 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

1

Kisunla

Eli Lilly

Phase 3

22

Tirazone

Sanofi

Phase 3

—3

Karxt

Bristol-Myers Squibb

Phase 3

34

Karx-EC

Bristol-Myers Squibb

Phase 3

25

Aquasol E

NNational Eye Institute (NEI)

Phase 3

—6

Naproxen Sodium

Bayer

Phase 3

—7

Exelon

Novartis

Phase 2

18

Actos

Takeda

Phase 2

19

Depakote

Teva

Phase 2

—10

Masitinib

AAB Science

Phase 3

—Show 37 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Dementia3 trials

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

Active, not recruiting·WWashington University School of Medicine·Phase 2/3·NCT01760005·490 enrolled

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Terminated·WWashington University School of Medicine·Phase 2/3·NCT06424236·73 enrolled

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

Completed·WWashington University School of Medicine·Phase 2/3·NCT04623242·194 enrolled

Early Alzheimer's Disease3 trials

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Terminated·Roche·Phase 3·NCT03444870·1,053 enrolled

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Terminated·Roche·Phase 3·NCT03443973·975 enrolled

A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Terminated·Roche·Phase 2·NCT04592341·192 enrolled

Alzheimer's Disease (AD)3 trials

A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)

Terminated·Roche·Phase 3·NCT05256134·25 enrolled

A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)

Terminated·Roche·Phase 3·NCT04374253·1,382 enrolled

A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)

Terminated·Roche·Phase 3·NCT04339413·116 enrolled

Concentration2 trials

A Study of A High Concentration Liquid Formulation Versus A Lyophilized Formulation of Gantenerumab in Healthy Volunteers

Completed·Roche·Phase 1·NCT01636531·120 enrolled

A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers

Completed·Roche·Phase 1·NCT02133937·31 enrolled

Tics2 trials

A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants

Completed·Roche·Phase 1·NCT02882009·48 enrolled

A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers

Completed·Roche·Phase 1·NCT02711423·18 enrolled

4 more indications

Alzheimer disease2 trials

A Study of Gantenerumab in Participants With Mild Alzheimer Disease

Completed·Roche·Phase 3·NCT02051608·389 enrolled

A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.

Completed·Roche·Phase 1·NCT00531804·60 enrolled

Prodromal Alzheimer's Disease1 trial

A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease

Completed·Roche·Phase 3·NCT01224106·799 enrolled

GAN1 trial

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients

Completed·Roche·Phase 1·NCT01656525·28 enrolled

ART1 trial

Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants

Completed·Roche·Phase 1·NCT03236844·114 enrolled

Details

Drug Info

Related News